Citation Report
List of articles citing

Single-dose clinical pharmacokinetic studies of gefitinib

DOI: 10.2165/00003088-200544110-00004
Clinical Pharmacokinetics, 2005, 44, 1165-77.

#	Paper	IF	Citations
117	Exploring the relationship between expression of cytochrome P450 enzymes and gefitinib pharmacokinetics. *Clinical Pharmacokinetics*, **2006**, 45, 633-44	6.2	54
116	Inhibition of Growth Factor Signaling by Small-Molecule Inhibitors of ErbB, Raf, and MEK. **2006**, 83-132		1
115	Interplay of distinct growth factors during epithelial mesenchymal transition of cancer progenitor cells and molecular targeting as novel cancer therapies. **2007**, 18, 1605-19		74
114	Differential metabolism of gefitinib and erlotinib by human cytochrome P450 enzymes. **2007**, 13, 3731-7		237
113	Pharmacology of Epidermal Growth Factor Inhibitors. **2007**, 22, 24-39		9
112	Pharmacokinetics of gefitinib in humans: the influence of gastrointestinal factors. **2007**, 341, 134-42		50
111	Determination of CH330331, a novel 4-anilinoquinazoline inhibitor of epidermal growth factor receptor tyrosine kinase, in human Caco-2 monolayers by high performance liquid chromatography with ultraviolet detection: application to a trans-epithelial transport study. **2007**, 854, 320-7		5
110	A phase I trial of intermittent high-dose gefitinib and fixed-dose docetaxel in patients with advanced solid tumors. **2007**, 59, 467-75		46
109	Evaluation of [(18)F]gefitinib as a molecular imaging probe for the assessment of the epidermal growth factor receptor status in malignant tumors. **2008**, 35, 1089-99		87
108	The relative bioavailability of gefitinib administered by granular formulation. **2008**, 62, 203-8		8
107	The efficacy and toxicity of EGFR in the settings of radiotherapy: Focus on published clinical trials. **2008**, 44, 2133-43		18
106	Overview of gefitinib in non-small cell lung cancer: an Asian perspective. **2009**, 39, 137-50		50
105	Management of EGFR-Mutant Non-Small Cell Lung Cancer: Focus on Gefitinib. **2009**, 1, CMT.S2122		
104	Effects of food on the relative bioavailability of lapatinib in cancer patients. **2009**, 27, 1191-6		101
103	Demonstration of the equivalent pharmacokinetic/pharmacodynamic dosing strategy in a multiple-dose study of gefitinib. **2009**, 8, 1438-47		30
102	Antitumor activity of a novel EGFR tyrosine kinase inhibitor against human lung carcinoma in vitro and in vivo. **2009**, 27, 1-11		7
101	Exploratory assessment of dose proportionality: review of current approaches and proposal for a practical criterion. **2009**, 8, 38-49		93

100	Gefitinib-phenytoin interaction is not correlated with the C-erythromycin breath test in healthy male volunteers. **2009**, 68, 226-37		29
99	Do gastrointestinal transit parameters influence the pharmacokinetics of gefitinib?. **2009**, 376, 7-12		22
98	Bioactivation of the epidermal growth factor receptor inhibitor gefitinib: implications for pulmonary and hepatic toxicities. **2009**, 22, 1736-42		63
97	Gefitinib: a review of its use in the treatment of locally advanced/metastatic non-small cell lung cancer. **2009**, 69, 2303-28		39
96	Gefitinib for the treatment of non-small-cell lung cancer. **2009**, 9, 17-35		35
95	Gefitinib-cyclodextrin inclusion complexes: physico-chemical characterization and dissolution studies. **2009**, 35, 1113-20		26
94	Clinical pharmacokinetics of tyrosine kinase inhibitors. **2009**, 35, 692-706		316
93	Epidermal growth factor receptor tyrosine kinase inhibitors: similar but different?. **2009**, 20, 856-66		43
92	Metabolism considerations for kinase inhibitors in cancer treatment. **2010**, 6, 1175-93		78
91	Gefitinib for the treatment of non-small-cell lung cancer. **2010**, 11, 1343-57		19
90	Therapeutic drug monitoring in cancer chemotherapy. **2010**, 2, 863-79		12
89	Phase I trial of the irreversible EGFR and HER2 kinase inhibitor BIBW 2992 in patients with advanced solid tumors. **2010**, 28, 3965-72		291
88	Clinical pharmacokinetics of tyrosine kinase inhibitors: focus on 4-anilinoquinazolines. *Clinical Pharmacokinetics*, **2011**, 50, 371-403	6.2	80
87	The Organization of the Gut and the Oral Absorption of Drugs: Anatomical, Biological and Physiological Considerations in Oral Formulation Development. **2011**, 27-48		5
86	In vitro dissolution/permeation system to predict the oral absorption of poorly water-soluble drugs: effect of food and dose strength on it. **2011**, 34, 401-7		36
85	Erlotinib efficacy and cerebrospinal fluid concentration in patients with lung adenocarcinoma developing leptomeningeal metastases during gefitinib therapy. **2011**, 67, 1465-9		81
84	The effect of different etiologies of hepatic impairment on the pharmacokinetics of gefitinib. **2011**, 68, 1485-95		24
83	The relationship between drug exposure and clinical outcomes of non-small cell lung cancer patients treated with gefitinib. **2011**, 28, 697-702		33

82	Molecular pharmacokinetic determinants of anticancer kinase inhibitors in humans. **2011**, 5, 77-92	10
81	Review of the treatment of non-small cell lung cancer with gefitinib. **2012**, 6, 407-21	20
80	Oral Chemotherapeutic Agents. **2012**, 1	1
79	Physicochemical properties of epidermal growth factor receptor inhibitors and development of a nanoliposomal formulation of gefitinib. **2012**, 101, 2763-76	20
78	Tyrosine kinase inhibitors and drug interactions: a review with practical recommendations. **2012**, 14, 94-101	24
77	Oral Drug Delivery. **2013**, 1083-1087	2
76	Clinical pharmacokinetics of tyrosine kinase inhibitors: implications for therapeutic drug monitoring. **2013**, 35, 562-87	63
75	In-vitro growth inhibition of chemotherapy and molecular targeted agents in hepatocellular carcinoma. **2013**, 24, 251-9	21
74	Critical appraisal of the role of gefitinib in the management of locally advanced or metastatic non-small cell lung cancer. **2014**, 7, 841-52	10
73	Gefitinib targets ZAP-70-expressing chronic lymphocytic leukemia cells and inhibits B-cell receptor signaling. **2014**, 5, e1439	12
72	Dacomitinib for the treatment of advanced or metastatic non-small-cell lung cancer. **2014**, 10, 813-22	10
71	A limited sampling strategy for estimation of the area under the plasma concentration-time curve of gefitinib. **2014**, 36, 24-9	10
70	A phase I study of AST1306, a novel irreversible EGFR and HER2 kinase inhibitor, in patients with advanced solid tumors. **2014**, 7, 22	23
69	Drug interactions with solid tumour-targeted therapies. **2014**, 89, 179-96	68
68	Enzyme- and transporter-mediated drug interactions with small molecule tyrosine kinase inhibitors. **2014**, 103, 3810-3833	25
67	Oral epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of non-small cell lung cancer: comparative pharmacokinetics and drug-drug interactions. **2014**, 40, 917-26	103
66	Mechanistic studies on the anticancer activity of 2,4-disubstituted quinazoline derivative. **2014**, 1840, 3123-30	8
65	Gefitinib. **2014**, 39, 239-64	30

64	Relationship Among Gefitinib Exposure, Polymorphisms of Its Metabolizing Enzymes and Transporters, and Side Effects in Japanese Patients With Non-Small-Cell Lung Cancer. **2015**, 16, 274-81	39
63	Chemical Proteomics Uncovers EPHA2 as a Mechanism of Acquired Resistance to Small Molecule EGFR Kinase Inhibition. **2015**, 14, 2617-25	35
62	Impact of single nucleotide polymorphisms on severe hepatotoxicity induced by EGFR tyrosine kinase inhibitors in patients with non-small cell lung cancer harboring EGFR mutations. **2015**, 90, 307-13	16
61	Individualized dosing of tyrosine kinase inhibitors: are we there yet?. **2015**, 20, 18-36	59
60	Evaluation of Three Small Molecular Drugs for Targeted Therapy to Treat Nonsmall Cell Lung Cancer. **2016**, 129, 332-40	17
59	Role of gefitinib in the targeted treatment of non-small-cell lung cancer in Chinese patients. **2016**, 9, 1291-302	7
58	Effect of food and acid-reducing agents on the absorption of oral targeted therapies in solid tumors. **2016**, 21, 962-76	35
57	Preclinical Data on Efficacy of 10 Drug-Radiation Combinations: Evaluations, Concerns, and Recommendations. **2016**, 9, 46-56	39
56	Effect of Food on the Pharmacokinetics of the Investigational Aurora A Kinase Inhibitor Alisertib (MLN8237) in Patients with Advanced Solid Tumors. **2016**, 16, 45-52	10
55	Simultaneous determination of gefitinib and its major metabolites in mouse plasma by HPLC-MS/MS and its application to a pharmacokinetics study. **2016**, 1011, 215-22	30
54	Mechanistic and Pharmacological Insights into Modulation of ABC Drug Transporters by Tyrosine Kinase Inhibitors. **2016**, 227-272	0
53	A Whole-Body Physiologically Based Pharmacokinetic Model of Gefitinib in Mice and Scale-Up to Humans. **2016**, 18, 228-38	25
52	Flipped script for gefitinib: A reapproved tyrosine kinase inhibitor for first-line treatment of epidermal growth factor receptor mutation positive metastatic nonsmall cell lung cancer. **2017**, 23, 203-214	6
51	Safe handling of oral antineoplastic medications: Focus on targeted therapeutics in the home setting. **2017**, 23, 350-378	15
50	Developments in pharmacotherapy for treating metastatic non-small cell lung cancer. **2017**, 18, 151-163	9
49	Editors' Highlight: Multiparametric Image Analysis of Rat Dorsal Root Ganglion Cultures to Evaluate Peripheral Neuropathy-Inducing Chemotherapeutics. **2017**, 156, 275-288	17
48	Induction of CYP1A1 increases gefitinib-induced oxidative stress and apoptosis in A549 cells. **2017**, 44, 36-43	10
47	Effect of Sustained Elevated Gastric pH Levels on Gefitinib Exposure. **2017**, 6, 517-523	12

46	A Review of Food-Drug Interactions on Oral Drug Absorption. **2017**, 77, 1833-1855	65
45	Novel therapeutic modalities and drug delivery - erlotinib liposomes modified with galactosylated lipid: in vitro and in vivo investigations. **2018**, 46, 1902-1907	21
44	Simultaneous quantification of volitinib and gefitinib in rat plasma by HPLC-MS/MS for application to a pharmacokinetic study in rats. **2017**, 40, 3782-3791	6
43	Fabrication of β-cyclodextrin-mediated single bimolecular inclusion complex: characterization, molecular docking, in-vitro release and bioavailability studies for gefitinib and simvastatin conjugate. **2017**, 69, 1304-1317	7
42	Gefitinib or erlotinib in previously treated non-small-cell lung cancer patients: a cohort study in Taiwan. **2017**, 6, 1563-1572	7
41	Kinase inhibitor pharmacokinetics: comprehensive summary and roadmap for addressing inter-individual variability in exposure. **2017**, 13, 31-49	37
40	Development of a nanoliposomal formulation of erlotinib for lung cancer and in vitro/in vivo antitumoral evaluation. **2018**, 12, 1-8	14
39	Phase I study of QLNC120, a novel EGFR and HER2 kinase inhibitor, in pre-treated patients with HER2-overexpressing advanced breast cancer. **2017**, 8, 36750-36760	3
38	Physiologically Based Pharmacokinetic Modeling to Evaluate the Systemic Exposure of Gefitinib in CYP2D6 Ultrarapid Metabolizers and Extensive Metabolizers. **2018**, 58, 485-493	9
37	Food Effect Study Design With Oral Drugs: Lessons Learned From Recently Approved Drugs in Oncology. **2019**, 59, 463-471	5
36	EGFR-TKIs in non-small-cell lung cancer: focus on clinical pharmacology and mechanisms of resistance. **2018**, 19, 727-740	15
35	Phase Ib Study of High-dose Intermittent Afatinib in Patients With Advanced Solid Tumors. **2018**, 19, e655-e665	4
34	Association of Variability and Pharmacogenomics With Bioequivalence of Gefitinib in Healthy Male Subjects. **2018**, 9, 849	17
33	FDA- and EMA-Approved Tyrosine Kinase Inhibitors in Advanced -Mutated Non-Small Cell Lung Cancer: Safety, Tolerability, Plasma Concentration Monitoring, and Management. **2019**, 9,	39
32	Safety, tolerability, and pharmacokinetics of simotinib, a novel specific EGFR tyrosine kinase inhibitor, in patients with advanced non-small cell lung cancer: results of a phase Ib trial. **2019**, 11, 4449-4459	1
31	A model of NSCLC microenvironment predicts optimal receptor targets. **2019**, 7, 147-161	
30	Evaluating the Role of Solubility in Oral Absorption of Poorly Water-Soluble Drugs Using Physiologically-Based Pharmacokinetic Modeling. **2020**, 107, 650-661	16
29	Alkalescent soda beverage caused the disappearance of gefitinib-induced rashes and decreased efficacy in a non-small-cell lung cancer patient treated with gefitinib: A case report. **2020**, 31, 101228	

28	Epithelial Transfer of the Tyrosine Kinase Inhibitors Erlotinib, Gefitinib, Afatinib, Crizotinib, Sorafenib, Sunitinib, and Dasatinib: Implications for Clinical Resistance. **2020**, 12,		3
27	Determinants of gefitinib pharmacokinetics in healthy Chinese male subjects: A pharmacogenomic study of cytochrome p450 enzymes and transporters. **2020**, 45, 1159-1167		2
26	Preconcentration and Detection of Gefitinib Anti-Cancer Drug Traces from Water and Human Plasma Samples by Means of Magnetic Nanoparticles. **2020**, 10,		8
25	Clinical implications of food-drug interactions with small-molecule kinase inhibitors. **2020**, 21, e265-e279		20
24	Anti-neoplastic agents for patients on peritoneal dialysis: A systematic review. **2020**, 150, 102947		3
23	A Phase 1 study of gefitinib combined with durvalumab in EGFR TKI-naive patients with EGFR mutation-positive locally advanced/metastatic non-small-cell lung cancer. **2021**, 124, 383-390		18
22	A phase Ib study of the highly selective MET-TKI savolitinib plus gefitinib in patients with EGFR-mutated, MET-amplified advanced non-small-cell lung cancer. **2021**, 39, 477-487		5
21	Expert-Augmented Computational Drug Repurposing Identified Baricitinib as a Treatment for COVID-19. **2021**, 12, 709856		3
20	Evaluating the utility of therapeutic drug monitoring in the clinical use of small molecule kinase inhibitors: a review of the literature. **2021**, 17, 803-821		3
19	EGFR inhibitors switch keratinocytes from a proliferative to a differentiative phenotype affecting epidermal development and barrier function. **2021**, 21, 5		5
18	Introduction to Kinase Antitargets. 329-364		1
17	Toxicology, Safety and Herb□rug Interactions in Cancer Therapy. **2010**, 293-340		1
16	Role for the epidermal growth factor receptor in chemotherapy-induced alopecia. *PLoS ONE*, **2013**, 8, e69368	3.7	11
15	Induction of autophagy is an early response to gefitinib and a potential therapeutic target in breast cancer. *PLoS ONE*, **2013**, 8, e76503	3.7	69
14	NSCLC depend upon YAP expression and nuclear localization after acquiring resistance to EGFR inhibitors. *Genes and Cancer*, **2017**, 8, 497-504	2.9	30
13	Safety Profiles and Pharmacovigilance Considerations for Recently Patented Anticancer Drugs: Lung Cancer. *Recent Patents on Anti-Cancer Drug Discovery*, **2019**, 14, 242-257	2.6	2
12	Safety Pharmacology: Similarities and Differences between Small Molecules and Novel Biopharmaceuticals. 1		
11	Clinical Pharmacology in Pediatrics. *Cancer Drug Discovery and Development*, **2014**, 625-659	0.3	

10	Targeting the ErbB Family in Head and Neck Cancer. *Current Cancer Research*, **2018**, 7-61	0.2	0
9	Drug-Drug Interactions, Safety, and Pharmacokinetics of EGFR Tyrosine Kinase Inhibitors for the Treatment of Non-Small Cell Lung Cancer. *Journal of the Advanced Practitioner in Oncology*, **2018**, 9, 189-200	0.7	11
8	Simultaneous quantitative detection of afatinib, erlotinib, gefitinib, icotinib, osimertinib and their metabolites in plasma samples of patients with non-small cell lung cancer using liquid chromatography-tandem mass spectrometry.. *Clinica Chimica Acta*, **2022**, 527, 1-10	6.2	0
7	Table_1.docx. **2018**,		
6	Gefitinib Inhibits Rifampicin-Induced CYP3A4 Gene Expression in Human Hepatocytes. **2022**, 7, 34034-34044		0
5	Pharmacokinetics of gefitinib in elderly patients with EGFR-mutated advanced non-small cell lung cancer: a prospective study. **2022**, 22,		0
4	Considering the Oral Bioavailability of Protein Kinase Inhibitors: Essential in Assessing the Extent of Drug□Drug Interaction and Improving Clinical Practice.		0
3	Off-label, but on target: the evidence needed to implement alternative dosing regimens of anticancer drugs. **2023**, 8, 100749		2
2	Effects of p450 Polymorphisms on the Clinical Outcomes of Gefitinib Treatment in Patients with Epidermal Growth Factor Receptor Mutation-Positive Non-Small Cell Lung Cancer. **2022**, 26, 582-588		0
1	Study on the hepatotoxicity and potential mechanism of gefitinib based on CYP450 in mice and AML12 cells.		0